Mortality was higher in the RSV cohort, with a 10.1% death rate, compared to 5.5% for flu. RSV infection showed a 52% higher ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

RSV is a virus that infects the nose, throat, and lungs and is often difficult to distinguish from other respiratory viruses, according to the Centers for Disease Control and Prevention.

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Protection against RSV derived from preF IgG antibodies waned 6 months after infection in an analysis of patients with confirmed disease and household contacts.

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.

Studies have found important benefits from the new RSV immunization and enhanced versions of the flu shot. Plus, the shingles ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older. CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) tod ...